Jan 27, 2022 / 07:30PM GMT
Unidentified Speaker Unknown Company-Company Representative
Today it is our pleasure to have Gracell Biotechnologies here with us, Gracell Biotechnologies is a global clinical stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies with its FastTCAR-T and TruUCAR technology platform.
We are excited to have William Cao, CEO and Founder of Gracell today to share their stories. And William, the floor is yours.
William Cao - Gracell Biotechnologies Inc. - Chief Executive Officer
Briefly, Gracell is listed in NASDAQ about 12 months ago. And right now our cash level is $300 million.
Our key technology platforms, FasTCAR, which is next-day manufacturing for autologous CAR-T therapy and TruUCAR, it's again, it's novel design, it's off-the-shelf CAR-T and it's a standalone therapy.
Myself is graduated from medical school in Fudan Medical University in Shanghai, China and I did post-doc training at Harvard and Stanford. And I got a PhD at the Medical College of Virginia and post-doc Harvard
Gracell Biotechnologies Inc at B Riley Oncology Conference (Virtual) Transcript
Jan 28, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers